Retatrutide's Phase 2 trial data (Jastreboff et al., NEJM 2023) identified a side-effect profile broadly consistent with other incretin-based therapies: Gastrointestinal : Nausea, vomiting, diarrhoea, and constipation were the most commonly reported adverse effects, particularly during dose escalation
To view a copy of this licence, visit About this article Cite this article Lewis, J.E., Montaner, M., Nuzzaci, D
Reduces the signs of aging through improving skin elasticity and firmness (4)
You can request a program or become a member
Coverage rules vary by state
By reducing melanin production, it helps prevent the formation of dark spots and pigmentation